STOCK TITAN
  1. Home
  2. Sec-filings
  3. RAPP
  4. [Form 4] Rapport Therapeutics, Inc. Insider Trading Activity

Rapport Therapeutics (RAPP) CEO logs multiple insider share sales

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Rapport Therapeutics, Inc. reported insider share sales by its chief executive officer and director on December 17, 2025, executed under Rule 10b5-1 trading plans adopted on December 12, 2024. The reporting person sold several blocks of common stock, including 2,441 shares at a weighted average price of $28.8378, 2,792 shares at $30.0365, and 600 shares at $31.036, with additional sales through an irrevocable trust at weighted average prices between roughly $28.84 and $31.04 per share, as disclosed in the footnotes.

Following these transactions, the reporting person beneficially owns 567,913 shares of common stock directly, and indirectly holds 30,895 shares through The Dorothy Ceesay Irrevocable Trust and 81,729 shares through The Ceesay Family Irrevocable Trust. The filing states that beneficial ownership of the trust-held shares is disclaimed except to the extent of any pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Ceesay Abraham
Role Chief Executive Officer
Sold 10,916 shs ($324K)
Type Security Shares Price Value
Sale Common Stock 2,441 $28.8378 $70K
Sale Common Stock 2,792 $30.0365 $84K
Sale Common Stock 600 $31.036 $19K
Sale Common Stock 2,147 $28.8425 $62K
Sale Common Stock 2,421 $30.0378 $73K
Sale Common Stock 515 $31.0396 $16K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 571,305 shares (Direct); Common Stock — 33,831 shares (Indirect, By Dorothy Ceesay Irrevocable Trust)
Footnotes (1)
  1. These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.62 to $29.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.72 to $30.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.78 to $31.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.62 to $29.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.72 to $30.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.75 to $31.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. Shares held by The Ceesay Family Irrevocable Trust u/t/d March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ceesay Abraham
(Last) (First) (Middle)
RAPPORT THERAPEUTICS, INC.
99 HIGH STREET, SUITE 2100
(Street)
BOSTON MA 02110
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
12/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/17/2025 S(1) 2,441 D $28.8378(2) 571,305 D
Common Stock 12/17/2025 S(1) 2,792 D $30.0365(3) 568,513 D
Common Stock 12/17/2025 S(1) 600 D $31.036(4) 567,913 D
Common Stock 12/17/2025 S(1) 2,147 D $28.8425(5) 33,831 I By Dorothy Ceesay Irrevocable Trust(8)
Common Stock 12/17/2025 S(1) 2,421 D $30.0378(6) 31,410 I By Dorothy Ceesay Irrevocable Trust(8)
Common Stock 12/17/2025 S(1) 515 D $31.0396(7) 30,895 I By Dorothy Ceesay Irrevocable Trust(8)
Common Stock 81,729 I By Ceesay Family Irrevocable Trust(9)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024.
2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.62 to $29.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.72 to $30.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.78 to $31.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.62 to $29.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
6. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.72 to $30.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
7. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.75 to $31.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
8. Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
9. Shares held by The Ceesay Family Irrevocable Trust u/t/d March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
/s/ Troy Ignelzi, Attorney-in-Fact 12/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did Rapport Therapeutics (RAPP) report in this filing?

The filing reports that a director and chief executive officer of Rapport Therapeutics, Inc. sold multiple blocks of the company’s common stock on December 17, 2025, and updates the number of shares the insider beneficially owns directly and through family trusts.

How many Rapport Therapeutics (RAPP) shares did the insider sell on December 17, 2025?

The reporting person sold several blocks of common stock, including 2,441, 2,792, and 600 shares directly, plus 2,147, 2,421, and 515 shares through The Dorothy Ceesay Irrevocable Trust, as listed in the transaction table.

At what prices were the Rapport Therapeutics (RAPP) shares sold by the insider?

The disclosed weighted average prices include $28.8378, $30.0365, and $31.036 per share for direct sales. Trust sales used weighted averages such as $28.8425, $30.0378, and $31.0396, with footnotes stating the underlying trades occurred in ranges from $28.62 to $31.15 per share.

How many Rapport Therapeutics (RAPP) shares does the insider own after these transactions?

After the reported sales, the insider beneficially owns 567,913 shares of Rapport Therapeutics common stock directly. Indirectly, 30,895 shares are held by The Dorothy Ceesay Irrevocable Trust and 81,729 shares are held by The Ceesay Family Irrevocable Trust.

What is the role of trading plans in these Rapport Therapeutics (RAPP) insider sales?

The filing states that the transactions were effected under Rule 10b5-1 trading plans adopted on December 12, 2024. Such plans allow insiders to pre-arrange trading instructions, and the trades are then executed according to those instructions.

Does the insider claim full beneficial ownership of the Rapport Therapeutics shares held in the family trusts?

The filing explains that the shares held by The Dorothy Ceesay Irrevocable Trust and The Ceesay Family Irrevocable Trust are reported, but beneficial ownership is disclaimed for Exchange Act purposes except to the extent of any pecuniary interest.